Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
13 Results for "
relapsing remitting
" in MedChemExpress (MCE) Product Catalog:
Products (13)
13 Results for "relapsing remitting" in MCE Product Catalog:
9
9 Publications Verification
Cat. No.: HY-P1240
CAS No.: 149635-73-4
Synonyms: Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat
Target:
Research Areas:
9
9 Publications Verification
Cat. No.: HY-P1240A
Synonyms: Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA
Target:
Research Areas:
9
9 Publications Verification
Cat. No.: HY-P1240B
Synonyms: Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate
Target:
Research Areas:
3
3 Cited Publications
Synonyms: AN100226; BG00002
Target:
Research Areas:
3
3 Cited Publications
Target:
Research Areas:
2
Research Areas:
Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
Cat. No.: HY-P99524
CAS No.: 1238217-55-4
Synonyms: GBR500
Target:
Research Areas:
Target:
Research Areas:
GSK239512 is a blood-brain barrier-permeable, orally active H3 receptor antagonist, with a human pKi ranging from <5.5 to 9.92 and a murine pKi ranging from 9.44 to 9.83. GSK239512 modulates cholinergic and monoaminergic neurotransmission, blocks the inhibitory feedback of H3 receptors, and increases the release of pro-cognitive neurotransmitters. GSK239512 induces oligodendrocyte precursor cell differentiation and restores myelin gene expression at the cellular level. GSK239512 reverses Scopolamine (HY-N0296)-induced memory deficits and improves recognition memory in animal models. GSK239512 can be used in research related to Alzheimer's disease, chronic traumatic encephalopathy, relapsing-remitting multiple sclerosis, and schizophrenia .
Cat. No.: HY-125726
CAS No.: 151057-28-2
Synonyms: (3'-sulfo)Galβ-Cer(d18:1/24:1); N-Nervonoyl Sulfatide; C24:1 Sulfatide
Research Areas:
Sulfo galactosylceramide (N-Nervonoyl Sulfatide; C24:1 Sulfatide) is a glycolipid and the major sulfolipid species in mature myelin. Sulfo galactosylceramide interacts with C-type lectins and immunoglobulin-like receptors, with the highest affinity for LMIR5. Sulfo galactosylceramide induces MCP-1 production by basophils but not mast cells, and increases NFAT activation via LMIR5. Sulfo galactosylceramide alleviates symptoms and improves survival in a mouse model of chronic relapsing-remitting experimental autoimmune encephalomyelitis (EAE), and reduces inflammatory lesions and the number of infiltrating mononuclear cells in the lumbar spinal cord of EAE mice.
Target:
Research Areas:
Tegomil fumarate is a derivative of Monomethyl fumarate (HY-103252) and an immunomodulator. Tegomil fumarate can be used for the study of relapsing remitting multiple sclerosis .
Cat. No.: HY-W062904
CAS No.: 248282-07-7
Synonyms: ABR-215062 sodium
Research Areas:
Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
Cat. No.: HY-13010R
CAS No.: 248281-84-7
Synonyms: ABR-215062 (Standard)
Target:
Research Areas:
Laquinimod (Standard) is the analytical standard of Laquinimod. This product is intended for research and analytical applications. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
Synonyms: ABR-215062-d5
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
